Merck donates anti-malarial candidate
Merck & Co has announced a licensing agreement with Medicines for Malaria Venture for an investigational drug against malaria for use in the developing world
Merck & Co has announced a licensing agreement with Medicines for Malaria Venture (MMV) for an investigational drug against malaria for use in the developing world .
Under the agreement, Merck, whose researchers discovered the candidate, has granted MMV an exclusive, royalty-free licence to develop it for use in malaria-endemic countries. MMV is a not-for-profit virtual research and development organisation. Merck retains the option to become MMV s development partner upon completion of the first Phase II clinical trial, but has committed not to profit ultimately from its use in developing countries.
TRIBUTE | Former Swiss Ambassador Dr Konji Sebati: The embodiment of selflessness, sacrifice
news24.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news24.com Daily Mail and Mail on Sunday newspapers.
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
socialnews.xyz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from socialnews.xyz Daily Mail and Mail on Sunday newspapers.